Other promising drugs that are currently under development for CU are a chemoattractant receptor-homologous molecule expressed on T<sub>H</sub>2 cell antagonist, a monoclonal antibody to Siglec-8 (AK002), Bruton tyrosine kinase inhibitors (fenebrutinib and Lou064), a spleen tyrosine kinase inhibitor, and dupilumab.